Repeated-dose toxicity of HSP27-binding heptapeptide in mice.
Heptapeptide, including seven amino acids of the PKC delta V5 region, which can bind HSP27 and abrogate HSP27-mediated resistance against IR and cisplatin ( Kim et al., 2007 ), was examined for single- and repeated-dose toxicity in mice. The single-dose experiment was performed with an intravenous and intraperitoneal injection of 100 mg/kg of heptapeptide, and the repeated-dose experiment was 14 doses over 28 days at 0, 5, 25, and 100 mg/kg of heptapeptide. Observations included clinical signs, mortality, body and organ weights, hematology, and serum biochemistry. No effects of heptapeptide on detected parameters were observed, and these findings indicated heptapeptide may be a possible therapeutic candidate without significant toxicity.
Lee
Hae-June
HJ
Division of Radiation Effects, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Lee
Yun-Sil
YS
D000818:Animals; D001772:Blood Cell Count; D001774:Blood Chemical Analysis; D001835:Body Weight / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D005260:Female; D055551:HSP27 Heat-Shock Proteins / Q000378:metabolism*; D006651:Histocytochemistry; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009842:Oligopeptides / Q000008:administration & dosage / Q000633:toxicity*; D011485:Protein Binding; D011897:Random Allocation
D055551:HSP27 Heat-Shock Proteins; D009842:Oligopeptides